banner2

Getting started
Active Pharmaceutical Ingredient

Active Pharmaceutical Ingredient - China Manufacturers, Factory, Suppliers

Active Pharmaceutical Ingredient, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

Epitalon CAS 307297-39-8 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Epitalon CAS 307297-39-8 Purity ≥98.0% (HPLC) High Purity
Read More

Tirzepatide CAS 2023788-19-2 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Tirzepatide CAS 2023788-19-2 Purity (HPLC) ≥99.0% Peptide Content ≥85.0% High Quality

Pyrimethamine CAS 58-14-0 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Pyrimethamine CAS 58-14-0 Assay 99.0%-101.0% (Titration, HPLC) High Purity

Nicotinamide CAS 98-92-0 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Nicotinamide CAS 98-92-0 Assay 99.0%-101.0% High Purity

Miconazole Nitrate CAS 22832-87-7 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Miconazole Nitrate CAS 22832-87-7 Assay 98.0%-102.0% Antifungal High Purity

Vismodegib CAS 879085-55-9 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Vismodegib (GDC-0449) CAS 879085-55-9 Assay ≥99.0% (HPLC)

Melatonin CAS 73-31-4 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — Melatonin CAS 73-31-4 Assay 98.5%-101.5% (HPLC) High Purity

banner4

Top Selling Products

Related Blog
Reviews

The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
Aripiprazole CAS 129722-12-9 USP43-NF38

Aripiprazole C23H27Cl2N3O2 448.39 2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1- piperazinyl]butoxy]-3,4-dihydro-; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril [129...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021)-Shanghai Ruifu Chemical Co., Ltd. participated in the exhibition

The 19th Beijing Conference and Exhibition on Instrumental Analysis (BCEIA 2021) was held on September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. Adhering to...
Pfizer seek emergency use mandate for Covid-19 antiviral pill Paxlovid

Pfizer is currently quest emergency use mandate from the FDA for its novel Covid-19 antiviral pill know as Paxlovid. This semen in the aftermath of Merck’s antiviral molnupiravir receive bles...
The “Summit on COVID-19 Diagnostics & Treatment”

The “Summit on COVID-19 Diagnostics & Treatment” September 27-29, 2021 at China International Exhibition Center (Tianzhu New Hall), Beijing. The outbreak of Corona Virus Disease 2019 (...

2022.12.15 17:21:42
2022.11.21 05:35:45
2022.08.16 22:34:31
2022.06.03 12:04:24
2022.01.09 20:32:39
2021.10.31 18:58:32

related search